Trials / Terminated
TerminatedNCT05181995
Safety and Efficacy of 50 mg NYX-783 QD vs. Placebo in PTSD
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of 50 mg NYX-783 Once Daily Compared to Placebo in Participants With Post-Traumatic Stress Disorder (PTSD)
- Status
- Terminated
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 121 (actual)
- Sponsor
- Aptinyx · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of 50 mg NYX-783 Once Daily Compared to Placebo in Participants with Post-Traumatic Stress Disorder (PTSD)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NYX-783 | NYX-783 |
| DRUG | Placebo | Placebo for 50 mg NYX-783 |
Timeline
- Start date
- 2021-12-13
- Primary completion
- 2023-03-30
- Completion
- 2023-03-30
- First posted
- 2022-01-10
- Last updated
- 2023-04-07
Locations
37 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05181995. Inclusion in this directory is not an endorsement.